Literature DB >> 23535159

The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes.

Alexander Marx1, Frederick Pfister, Berthold Schalke, Güher Saruhan-Direskeneli, Arthur Melms, Philipp Ströbel.   

Abstract

The thymus plays distinct roles in the pathogenesis of the different Myasthenia gravis (MG) subtypes. Inflammatory, neoplastic and age-related alterations of the thymus are of pivotal relevance for the initiation of anti-acetylcholine receptor (AChR) autoimmunity in early onset MG, thymoma-associated MG and, likely, late onset MG, respectively. By contrast, the thymus is presumably not related to MG that is due to autoantibodies to the muscle specific kinase, MuSK. Finally, the role of the thymus is still obscure in MG defined by antibodies against the agrin receptor LRP4 and in MG without all of the above autoantibdies (triple sero-negative MG) since these MG subtypes have been described only recently and thymectomy has not been their standard treatment. This review aims to give an update on intrathymic mechanisms of tolerance breakdown in MG, including abnormal T cell selection and activation, the role of thymic myoid cells, the autoimmune regulator (AIRE) and regulatory T cells.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23535159     DOI: 10.1016/j.autrev.2013.03.007

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  89 in total

Review 1.  Paraneoplastic disorders in thymoma patients.

Authors:  Amelia Evoli; Eric Lancaster
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

Review 2.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Authors:  Jason A Vander Heiden; Panos Stathopoulos; Julian Q Zhou; Luan Chen; Tamara J Gilbert; Christopher R Bolen; Richard J Barohn; Mazen M Dimachkie; Emma Ciafaloni; Teresa J Broering; Francois Vigneault; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

Review 4.  Paraneoplastic disorders.

Authors:  Eric Lancaster
Journal:  Continuum (Minneap Minn)       Date:  2015-04

Review 5.  Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.

Authors:  Elizabeth A Lippner; David B Lewis; William H Robinson; Tamiko R Katsumoto
Journal:  Curr Treat Options Oncol       Date:  2019-06-22

6.  Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity.

Authors:  Roberto Massa; Giulia Greco; Manuela Testi; Emanuele Rastelli; Chiara Terracciano; Erica Frezza; Matteo Garibaldi; Girolama A Marfia; Franco Locatelli; Nicola B Mercuri; Eugenio Pompeo; Giovanni Antonini; Marco Andreani
Journal:  J Neurol       Date:  2019-02-11       Impact factor: 4.849

Review 7.  Myasthenia gravis - autoantibody characteristics and their implications for therapy.

Authors:  Nils Erik Gilhus; Geir Olve Skeie; Fredrik Romi; Konstantinos Lazaridis; Paraskevi Zisimopoulou; Socrates Tzartos
Journal:  Nat Rev Neurol       Date:  2016-04-22       Impact factor: 42.937

8.  Commentary on "Randomized trial of thymectomy in myasthenia gravis".

Authors:  Alexandar Tzankov
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

9.  A crucial first randomized controlled trial of thymectomy in non-thymomatous myasthenia gravis.

Authors:  Pierre R Bourque; Jodi Warman Chardon
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 10.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.